A key aim for DMD therapies is to prevent myonecrosis and to directly stabilise the myofibres, ideally by replacing the non-functional dystrophin using various gene delivery or molecular strategies, with recent promising progress (Verhaart and Aartsma-Rus, 2019). This evidence concerns the gene DMD and Duchenne muscular dystrophy.